2 Drug Stocks Squeezing Shorts

BLUE and TXMD are signaling higher opens this morning

Jun 15, 2018 at 9:23 AM
facebook twitter linkedin

Shares of bluebird bio Inc (NASDAQ:BLUE) are up 0.5% in electronic trading, after the company reported positive early stage trial data for its LentiGlobin gene therapy in patients with sickle cell disease and thalassemia -- two blood disorders. Bluebird said it expects to submit a marketing application in the European Union (EU) later this year for LentiGlobin as a thalassemia treatment.

Looking at the charts, BLUE stock has been in a channel of higher highs and lows since bouncing off its 180-day moving average in early April -- and this rising trendline has continued to serve as support. And while the security remains off its mid-March record peak at $236.17, it's still maintaining a 10.6% year-to-date return, based on last night's close at $197.

Should the drug stock continue to climb, a continued round of short covering could create even bigger tailwinds. Although short interest is down 4.7% in the most recent reporting period, there are still 3.59 million BLUE shares sold short -- representing almost 8% of the security's float, or seven times the average daily pace of trading.

TherapeuticsMD Inc (NASDAQ:TXMD) stock is also signaling a positive open, up 5.1% ahead of the bell. J.P. Morgan Securities initiated coverage on the women's health specialist with an "overweight" rating and $11 price target -- a roughly 60% premium to last night's close at $6.88, and territory not charted since late 2015.

TXMD stock has been climbing up the charts since bottoming at a year-to-date low of $4.64 on March 27, gaining more than 48%. What's more, the shares topped out at an annual high of $7.66 one week ago today, and have since pulled back to support at their 20-day moving average.

Short sellers could help propel the security even higher. The 55.10 million TXMD shares currently sold short account for almost one-third of the stock's available float, or 20 days' worth of pent-up buying demand, at the average pace of trading.


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!